Sickle Cell Disease Drug approved in EU to interfere with Pathogenesis

被引：0

|

作者：

Freye, Reimund

机构：

来源：

ACTA HAEMATOLOGICA | 2022年 / 145卷 / 05期

关键词：

BRENTUXIMAB VEDOTIN;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：573 / 573

页数：1

相关论文

共 50 条

[41] PATHOGENESIS OF HYPOSTHENURIA IN PERSONS WITH SICKLE CELL ANEMIA OR THE SICKLE CELL TRAIT
SCHLITT, L
KEITEL, HG
PEDIATRICS, 1960, 26 (02) : 249 - 254
[42] Heme-induced cell adhesion in the pathogenesis of sickle-cell disease and inflammation
Wagener, FADTG
Abraham, NG
van Kooyk, Y
de Witte, T
Figdor, CG
TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (02) : 52 - 54
[43] Sickle Cell AnaemiaProgress in Pathogenesis and Treatment
Samir K. Ballas
Drugs, 2002, 62 : 1143 - 1172
[44] PATHOGENESIS OF HYPOSTHENURIA IN SICKLE CELL ANEMIA
KEITEL, HG
PEDIATRICS, 1960, 26 (06) : 1051 - 1052
[45] THE PATHOGENESIS OF SICKLE CELL ANEMIA A REVIEW
SINGER, K
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1951, 21 (09) : 858 - 865
[46] The Opioid Drug Epidemic and Sickle Cell Disease: Guilt by Association
Ruta, Nadia S.
Ballas, Samir K.
PAIN MEDICINE, 2016, 17 (10) : 1793 - 1798
[47] Advances in new drug therapies for the management of sickle cell disease
Ataga, Kenneth I.
Desai, Payal C.
EXPERT OPINION ON ORPHAN DRUGS, 2018, 6 (05): : 329 - 343
[48] Drug for treatment of sickle cell disease patients extends life
Dawson, GA
JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2003, 95 (06) : 420 - 420
[49] Gene Therapy for Sickle Cell Disease: Striking a Balance Between Approved Therapies and Clinical Trials
Unguru, Yoram
Okoro, Evelyn
Okoro, Akpo
AMERICAN JOURNAL OF BIOETHICS, 2025, 25 (04): : 151 - 153
[50] Crizanlizumab approved in Europe for Prevention of recurrent vaso-occlusive Crises in Sickle Cell Disease
不详
TRANSFUSION MEDICINE AND HEMOTHERAPY, 2021, 48 (01) : 69 - 69

← 1 2 3 4 5 →